ARM's 2022 Cell & Gene State of the Industry Briefing

The Alliance for Regenerative Medicine’s annual Cell & Gene State of the Industry Briefing, a top-level gathering for key stakeholders in the field. This webinar includes ARM’s annual yearly update on the sector’s progress, followed by two panel sessions featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year.

Introduction & Industry Update
Janet Lambert, CEO, Alliance for Regenerative Medicine
Emile Nuwaysir, Ph.D., CEO, Ensoma; Chairman, Alliance for Regenerative Medicine (ARM); Chairman, BlueRock Therapeutics

2022: A Banner Year for Rare Genetic Disease Therapies?
Bob Smith, Senior Vice President, Global Gene Therapy Business, Pfizer Inc. (Moderator)
Harold Bernstein, M.D., Ph.D., Chief Medical Officer and Senior Vice President, BioMarin
Jason Cole, Chief Business Officer, bluebird bio
Bobby Gaspar, M.D., Ph.D., CEO, Orchard Therapeutics
Suma Krishnan, Founder and Chief Operating Officer, Krystal Biotech

Next Generation Therapies to Fight Cancer
Robert Ang, CEO, Vor Biopharma (Moderator)
Osvaldo Flores, Ph.D., CEO, Century Therapeutics
Steven Kelly, President and CEO, Carisma Therapeutics
Alison Moore, Ph.D., Chief Technical Officer, Allogene Therapeutics